% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Tretter:277913,
author = {C. Tretter$^*$ and N. de Andrade Krätzig and M. Pecoraro
and S. Lange and P. Seifert and C. von Frankenberg and J.
Untch and G. Zuleger and M. Wilhelm and D. P. Zolg and F. S.
Dreyer and E. Bräunlein and T. Engleitner and S. Uhrig and
M. Boxberg$^*$ and K. Steiger$^*$ and J. Slotta-Huspenina
and S. Ochsenreither$^*$ and N. von Bubnoff$^*$ and S.
Bauer$^*$ and M. Börries$^*$ and P. J. Jost$^*$ and K.
Schenck$^*$ and I. Dresing$^*$ and F. Bassermann$^*$ and H.
Friess and D. Reim and K. Grützmann$^*$ and K. Pfütze$^*$
and B. Klink$^*$ and E. Schröck$^*$ and B. Haller and B.
Kuster$^*$ and M. Mann and W. Weichert$^*$ and S.
Fröhling$^*$ and R. Rad$^*$ and M. Hiltensperger$^*$ and A.
Krackhardt$^*$},
title = {{P}roteogenomic analysis reveals {RNA} as a source for
tumor-agnostic neoantigen identification.},
journal = {Nature Communications},
volume = {14},
number = {1},
issn = {2041-1723},
address = {[London]},
publisher = {Nature Publishing Group UK},
reportid = {DKFZ-2023-01572},
pages = {4632},
year = {2023},
abstract = {Systemic pan-tumor analyses may reveal the significance of
common features implicated in cancer immunogenicity and
patient survival. Here, we provide a comprehensive
multi-omics data set for 32 patients across 25 tumor types
for proteogenomic-based discovery of neoantigens. By using
an optimized computational approach, we discover a large
number of tumor-specific and tumor-associated antigens. To
create a pipeline for the identification of neoantigens in
our cohort, we combine DNA and RNA sequencing with MS-based
immunopeptidomics of tumor specimens, followed by the
assessment of their immunogenicity and an in-depth
validation process. We detect a broad variety of
non-canonical HLA-binding peptides in the majority of
patients demonstrating partially immunogenicity. Our
validation process allows for the selection of 32 potential
neoantigen candidates. The majority of neoantigen candidates
originates from variants identified in the RNA data set,
illustrating the relevance of RNA as a still understudied
source of cancer antigens. This study underlines the
importance of RNA-centered variant detection for the
identification of shared biomarkers and potentially relevant
neoantigen candidates.},
cin = {MU01 / HD01 / B340 / BE01 / FR01 / ED01 / DD01},
ddc = {500},
cid = {I:(DE-He78)MU01-20160331 / I:(DE-He78)HD01-20160331 /
I:(DE-He78)B340-20160331 / I:(DE-He78)BE01-20160331 /
I:(DE-He78)FR01-20160331 / I:(DE-He78)ED01-20160331 /
I:(DE-He78)DD01-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37532709},
doi = {10.1038/s41467-023-39570-7},
url = {https://inrepo02.dkfz.de/record/277913},
}